9 research outputs found

    AGRONOMIC TRAITS AND PROTEIN PATTERNS FOR SOME PROMISING WHEAT SEMIDWARF MUTANT LINES

    Get PDF
    Two field experiments were carried out to evaluate six mutant lines having a good agronomic potential comparing with their original varieties Sids5, Sids6 and Sids7. The results showed signif-icant decrease in plant height for all semidwarf mutant lines. The reduction of plant height reached to 19.83% comparing with the original varieties. Some semidwarf mutant lines (line 5-1, line 6-1 and line 7-1) exhibited highly significant values for spike length, number of spikes/plant and grain yield/plant as compared to their original varieties. The original varieties manifested highly significant values for number of grains/spike as compared to their all semidwarf mutant lines. The results indicated that wheat semidwarf mutants of line 5-1, line 6-1 and line 7-1 are promising mu-tant lines, since they gave high grain yield. All studied genotypes were electrophoreticaly ana-lyzed for grain water-soluble proteins. The dis-crimination of such mutant lines and their parental varieties revealed differences in their banding pat-terns and occurrence of genetic variation between such genotypes. The electrophoretic analyses of proteins revealed some newly induced bands such as bands with molecular weights of 114.04, 87.82, 41.55 and 11.90 kDa. Such newly bands, which were not existed in the unirradiated varieties, may be originated from gamma radiation effects. It is expected that gamma rays modified the structure of some genes in the mutant lines, and these modi-fications appeared as absence of protein bands with molecular weights of 72.60 kDa in sids5 and 24.39 kDa in Sids6. The variety Sids7 exhibited the highest numbers of new protein bands after irradiation. The results revealed positive relation

    In-vivo and in-vitro effectiveness of three insecticides types for eradication of the tick Rhipicephalus sanguineus in dogs

    Get PDF
    Background: External parasites contribute to extensive harmful impacts on their hosts which is why control and eradication of external parasites have been included in all biosecurity plans of dog houses.Aim: To evaluate the in-vitro and in-vivo effectiveness of chemicals like Doramectin injectable and Fipronil 50 mg/ml drops and herbal mixes eco-friendly insecticides like phenylpyrazole–garlic–camphor mix spray for combating the external parasitism in dogs and their influence on the hematological, biochemical, and cortisol (CORT) profiles.Method: The in-vitro effectiveness of the insecticides was conducted by using a total of 216 developmental stage Rhipicephalus sanguineus (72 adults, 72 larvae, and 72 eggs) designed into three replicates of petri dishes (3 plates × 8 units × 3 stages/replicate); each replicate was exposed to 1 ml insecticide. The number of surviving ticks was recorded after 0, 2, 4, 8, 16, and 24 hours. Sixteen Rottweiler male dogs aged 1 year and 45.5 kg were divided into four groups. Three groups (G1, G2, and G3) were experimentally infested with R. sanguineus ticks 3–4 weeks post-dog arrival and kept under observation from zero-time of experimental infestation for 1–2 weeks. The three experimentally infested dog groups were treated with Doramectin injectable, Fipronil 50 mg/ml drops, and phenylpyrazole–garlic–camphor mix spray, respectively, and the fourth group was designed as a negative control.  A total of 144 samples, including 48 ethylenediaminetetraacetic acid blood, 48 whole blood, and 48 sera samples, were collected.Results: The in-vitro efficacy revealed highly significant (p < 0.01) 100% killing efficacy that was achieved after 8 hours in Doramectin and Fipronil 50 mg/ml and 24 hours in phenylpyrazole–garlic–camphor mix. The in-vivo trials revealed highly significant (p < 0.01) improvements of red blood cells, hematocrit, mean corpuscular hemoglobin concentrations, platelets, total and differential leukocytic counts, erythrocyte sedimentation rates in the second hour, total protein, creatinine, alanine aminotransferase, urea, glucose, triglycerides, total cholesterol, and CORT levels in the 2-week (P1) and 4-week posttreatment (P2) samples in Dormectin, Fipronil 50 mg/ml, and phenylpyrazole–garlic–camphor mix-treated dogs with more pronounced recovery in phenylpyrazole–garlic–camphor mix spray-treated dogs.Conclusion: The insecticides were able to provide a high level of protection against experimental infestation with concern to the different modes of application. Phenylpyrazole–garlic–camphor mix spray (eco-friendly) achieved higher insecticidal action compared to the chemicals

    Heterologous Expression of Cyanobacterial Cyanase Gene (CYN) in Microalga Chlamydomonas reinhardtii for Bioremediation of Cyanide Pollution

    No full text
    Recombinant DNA technology offered the creation of new combinations of DNA segments that are not found together in nature. The present study aimed to produce an ecofriendly bioremediation model to remediate cyanide pollution from a polluted marine system. Cyanide is a known toxic compound produced through natural and anthropogenic activities. An Agrobacterium-tumefaciens-mediated genetic transformation technique was used to generate transformed Chlamydomonas reinhardtii using plant expression vector pTRA-K-cTp carries isolated coding sequence of the cyanobacterial cyanase gene (CYN) isolated from Synechococcus elongatus (PCC6803). qRT-PCR analysis showed the overexpression of CYN in transgenic C. reinhardtii, as compared with the respective wild type. Growth parameters and biochemical analyses were performed under cyanide stress conditions using transgenic and wild C. reinhardtii for evaluating the effect of the presence of the cyanobacterial cyanase gene in algae. The transgenic C. reinhardtii strain (TC. reinhardtii-2) showed promising results for cyanide bioremediation in polluted water samples. Cyanide depletion assays and algal growth showed a significant resistance in the transgenic type against cyanide stress, as compared to the wild type. Genetically modified alga showed the ability to phytoremediate a high level of potassium cyanide (up to150 mg/L), as compared to the wild type. The presence of the CYN gene has induced a protection response in TC. Reinhardtii-2, which was shown in the results of growth parameter analyses. Therefore, the present study affirms that transgenic C. reinhardtii by the CYN coding gene is a potential effective ecofriendly bioremediator model for the remediation of cyanide pollutants in fresh water

    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

    No full text
    Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient

    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

    No full text
    WOS: 000468732700018PubMed ID: 31054483Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient.ESC - EORP; AmgenAmgen; Eli LillyEli Lilly; PfizerPfizer; SanofiSanofi-Aventis; Ferrer; Novo NordiskNovo NordiskThe EUROASPIRE V survey was carried out under the auspices of the ESC - EORP. Since the start of EORP, the following companies have supported the programme: Amgen, Eli Lilly, Pfizer, Sanofi, Ferrer and Novo Nordisk. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript

    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

    No full text
    Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8\% of the patients and had been started or increased in intensity in 11.7\%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8\% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient

    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

    No full text
    corecore